Xeris Biopharma Holdings (XERS) Change in Receivables (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Change in Receivables for 7 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Receivables fell 73.06% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2026 stood at $5.1 million (down 52.33% YoY), and the FY2025 full-year result was $10.6 million, up 773.15% from the prior year.
• Change in Receivables eased to $1.8 million in Q2 2026 per XERS's latest filing, from $5.2 million in the prior quarter.
• Across five years, Change in Receivables topped out at $15.7 million in Q3 2023 and bottomed at -$6.8 million in Q4 2023.
• Historically, Change in Receivables has averaged $2.3 million across 5 years, with a median of $1.8 million in 2022.
• The widest YoY moves for Change in Receivables: up 891.5% in 2024, down 6043.33% in 2024.
• Over 5 years, Change in Receivables stood at $3.3 million in 2022, then tumbled by 304.38% to -$6.8 million in 2023, then soared by 89.32% to -$723000.0 in 2024, then tumbled by 273.58% to -$2.7 million in 2025, then soared by 167.01% to $1.8 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered $1.8 million, $5.2 million, and -$2.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.